Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Stock Information for Oncolytics Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.